Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587418 · ClinicalTrials.gov registry record · NA
L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00587418: Completed NA study, sponsored by Mayo Clinic.
NCT00587418 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00587418, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
Chronic renal insufficiency is a common and important health problem that causes morbidity and mortality among patients who have undergone liver transplantation. It is mainly caused by drugs (calcineurin inhibitors) that are used to prevent or treat rejection and once established, there is no effective treatment. This research investigates whether L-arginine can reverse the effects of calcineurin inhibitors on the kidneys and thus prevent renal insufficiency in liver transplant recipients.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT L-arginine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00587418
The ClinicalTrials.gov registry entry for NCT00587418 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00587418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00587418 about?
NCT00587418 is a clinical study titled "L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients". Chronic renal insufficiency is a common and important health problem that causes morbidity and mortality among patients who have undergone liver transplantation. It is mainly caused by drugs (calcineurin inhibitors) that are used to prevent or treat rejection and once established, there is no effect...
What is the current status of trial NCT00587418?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2008-11. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00587418?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), L-arginine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00587418?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.